Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,328 active trials222 approved drugs2,775 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,686 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04567615 | A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors | completed | Phase 2 | 266 | Bristol-Myers SquibbINDUSTRY | 17 | Jan 8, 2026 | clinicaltrials |
| NCT06173037 | RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | completed | Phase 2 | 43 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 |
| clinicaltrials |
| NCT05054725 | Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies | completed | Phase 2 | 47 | Revolution Medicines, Inc.INDUSTRY | 10 | Jan 6, 2026 | clinicaltrials |
| NCT05348811 | HAIC Combined With Donafenib and Sintilimab for Unresectable ICC | completed | Phase 2 | 25 | Zhongda HospitalOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT06029127 | A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer | completed | Phase 2 | 35 | BeiGeneINDUSTRY | 2 | Jan 5, 2026 | clinicaltrials |
| NCT02473133 | Study of Interest of Personalized Radiotherapy Dose Redistribution in Patients With Stage III NSCLC(RTEP7) | completed | Phase 2 | 158 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT02490891 | Study of the Angiogenesis by PET/CT in Patients With Lymphoma(RGDLymphome) | completed | Phase 2 | 21 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT02617745 | Impact of the Platelet Level in Patients Treated for Glioblastoma With Temozolomid(GLIOPLAK) | completed | Phase 2 | 244 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT03199274 | Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer | completed | Phase 2 | 104 | Thomas Jefferson UniversityOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT03212170 | FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer | completed | Phase 2 | 21 | University of Wisconsin, MadisonOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04031534 | Study of Hypoxia Measured in F-Miso PET/Scan and MRI in Patients With Squamous Cells Carcinoma(HYPONECK) | completed | Phase 2 | 16 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04553939 | Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer | completed | Phase 2 | 50 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04224337 | Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma | completed | Phase 2 | 16 | Seoul National University HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT04227509 | Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma | completed | Phase 2 | 53 | Seoul National University HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT00255346 | Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | completed | Phase 2 | 68 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT03345420 | Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer(NOVEMBER) | completed | Phase 2 | 102 | University of UtahOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07304388 | HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICC | completed | Phase 2 | 96 | Sun Yat-sen UniversityOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT05380713 | ......SMARTEST Trial...... | completed | Phase 2 | 30 | University Health Network, TorontoOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT06562673 | Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma(IACE-OS) | completed | Phase 1 / Phase 2 | 10 | Shanghai 6th People's HospitalOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT06322342 | Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent | completed | Phase 2 | 18 | Reveal Pharmaceuticals Inc.INDUSTRY | 1 | Dec 26, 2025 | clinicaltrials |
| NCT01658878 | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer(CheckMate040) | completed | Phase 1 / Phase 2 | 657 | Bristol-Myers SquibbINDUSTRY | 13 | Dec 24, 2025 | clinicaltrials |
| NCT06511895 | AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) | completed | Phase 2 | 57 | Dizal PharmaceuticalsINDUSTRY | 1 | Dec 24, 2025 | clinicaltrials |
| NCT03105336 | A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma(ZUMA-5) | completed | Phase 2 | 159 | Kite, A Gilead CompanyINDUSTRY | 2 | Dec 23, 2025 | clinicaltrials |
| NCT03745794 | Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery | completed | Phase 2 | 136 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT04154943 | Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma | completed | Phase 2 | 79 | Regeneron PharmaceuticalsINDUSTRY | 3 | Dec 23, 2025 | clinicaltrials |
| NCT05005429 | Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma(BIMES) | completed | Phase 2 | 47 | Fundación GECPOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06120712 | A Study of GC101 TIL in Advanced Melanoma (BZ)(MIZAR-002) | completed | Phase 1 / Phase 2 | 18 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT01665794 | Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 25 | University of ChicagoOTHER | 2 | Dec 22, 2025 | clinicaltrials |
| NCT03290079 | Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors | completed | Phase 2 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT05120570 | PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation | completed | Phase 1 / Phase 2 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT00466674 | Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning(IFM 2005-03) | completed | Phase 2 | 13 | Hospices Civils de LyonOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT01496976 | Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL | completed | Phase 2 | 45 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05115630 | Off-the-shelf NK Cells + SCT for Myeloid Malignancies | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05465343 | Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE) | completed | Phase 2 | 24 | Peking Union Medical CollegeOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT02611037 | Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma | completed | Phase 2 | 34 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04965090 | A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05024513 | Biliary Drainage Plus HAIC in Locally Advanced pCCA | completed | Phase 2 | 127 | Peking UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT02461888 | Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.(MUKEight) | completed | Phase 2 | 112 | University of LeedsOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT03317899 | Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma | completed | Phase 2 | 77 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT04091022 | Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer | completed | Phase 2 | 64 | University of Alabama at BirminghamOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05342636 | A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) | completed | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Dec 17, 2025 | clinicaltrials |
| NCT02314364 | A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC | completed | Phase 2 | 27 | Massachusetts General HospitalOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT03534947 | A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma(SONIB) | completed | Phase 2 | 16 | Melanoma Institute AustraliaOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT03910387 | Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer | completed | Phase 2 | 23 | Emory UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05001347 | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors | completed | Phase 2 | 25 | I-Mab Biopharma US LimitedINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05419362 | GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer | completed | Phase 2 | 42 | Genome & CompanyINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT01349101 | A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors | completed | Phase 2 | 78 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT02005289 | Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL | completed | Phase 2 | 41 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT03310957 | Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer | completed | Phase 1 / Phase 2 | 185 | Seagen Inc.INDUSTRY | 4 | Dec 12, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Jan 8, 2026source: clinicaltrials